Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

China flag China · Delayed Price · Currency is CNY
8.95
+0.04 (0.45%)
Apr 29, 2026, 3:04 PM CST
11.74%
Market Cap 14.85B
Revenue (ttm) 2.56B
Net Income (ttm) 693.78M
Shares Out 1.67B
EPS (ttm) 0.42
PE Ratio 21.25
Forward PE n/a
Dividend 0.25 (2.82%)
Ex-Dividend Date n/a
Volume 15,973,124
Average Volume 22,535,212
Open 9.20
Previous Close 8.91
Day's Range 8.85 - 9.20
52-Week Range 7.96 - 13.06
Beta 0.54
RSI 34.28
Earnings Date Mar 31, 2026

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life det... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 2,505
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300009
Full Company Profile

Financial Performance

In 2025, SHE:300009's revenue was 2.65 billion, an increase of 4.36% compared to the previous year's 2.54 billion. Earnings were 735.19 million, an increase of 4.00%.

Financial Statements

News

There is no news available yet.